Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
luvixasertib (CFI-402257) / Treadwell Therap
NCT05601440: Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer	Recruiting	2	484	Canada	RP-6306, Lunresertib, Gemcitabine, Observation, Niraparib, Fulvestrant, RP-3500, Camonsertib	Canadian Cancer Trials Group	Breast Cancer	12/27	06/28
CCTG IND.236, NCT03568422: CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer	Active, not recruiting	1/2	37	Canada	CFI-402257, Paclitaxel	Canadian Cancer Trials Group, Stand Up To Cancer, Canadian Breast Cancer Foundation, Ontario Institute for Cancer Research	Breast Cancer	11/22	12/24
TWT-203, NCT05251714: CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer	Recruiting	1/2	44	US	CFI-402257, 2257, 402257, Fulvestrant, Faslodex	Treadwell Therapeutics, Inc	Advanced Solid Tumor, Breast Cancer	08/25	08/25
CFI-402257-CL-001, NCT02792465: A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors	Active, not recruiting	1	52	Canada	CFI-402257, Fulvestrant	University Health Network, Toronto	Advanced Solid Cancers, Breast Cancer	05/27	05/27